Divi's Laboratories News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Divi's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news and updates on Divi's Laboratories from all sources in a single place.

Divi's Laboratories Ltd.

11 Jun 2026

6743.00

-0.35%

Company Update

Divis Laboratories Ltd - 532488 - Information Regarding Deduction Of Income Tax At Source From Payment …

BSE India

As per enclosed letter.

pdf

Divi's Laboratories Ltd.

04 Jun 2026

6743.00

-0.35%

Company Update

Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copies of Newspaper Publication - Notice to the shareholders regarding transfer of unclaimed dividends and equity shares to IEPF

pdf

Divi's Laboratories Ltd.

29 May 2026

6743.00

-0.35%

Earnings Call

Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Submission of transcript of Earnings Conference Call held on May 23, 2026

pdf

Divi's Laboratories Ltd.

28 May 2026

6743.00

-0.35%

Valuation

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 15.3% / 20% / 18.2% for the period of FY26-FY28.

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

25 May 2026

6743.00

-0.35%

Company Update

Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publications regarding audited financial results of the Company for the quarter and year ended March 31, 2026

pdf

Divi's Laboratories Ltd.

25 May 2026

6743.00

-0.35%

Divi's Laboratories (DIVI IN) Q4FY26 Result Update EBITDA miss; Peptide opportunities key for growth ACCUMULATE

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY26 EBITDA missed our estimates due to lower gross margin. Revenues were largely aided by CS segment and currency tailwind. Mgmt indicated inventory levels may increase further in Q1FY27E to ensure uninterrupted operations. We expect stable margins in FY27 and expect revenue to accelerate from FY28 as commencement of some CDMO and contrast media contracts along with peptide revenue scale up. Our FY27E/FY28E EPS estimates stand cut by 2-4%. We expect 19% EBITDA and PAT CAGR over FY26-28E. At CMP, stock is trading at 52x...

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

24 May 2026

6743.00

-0.35%

Divi's Labs (HOLD): Margin headwinds to persist in near term

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 3.4%/10%/1 below our estimates. EBITDA Margin was reported 235 bps below our estimates at 33%

Divi's Laboratories .. has an average target of 6702.67 from 6 brokers.

Divi's Laboratories Ltd.

23 May 2026

6743.00

-0.35%

Corp. Note

Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Dividend Updates

BSE India

The Board of Directors at its meeting held on May 23, 2026 have recommended a dividend of Rs. 30/- per share (i.e. @1500%), subject to approval at the ensuing Annual General Meeting.

pdf